Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00196989 · ClinicalTrials.gov registry record · Phase 2
Study In People With Type 2 Diabetes
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT00196989: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00196989 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 448 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00196989, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).
Primary Outcome
Improvement in glucose control was measured by means of reduction in glycated hemoglobin (Hb) levels in blood.
Interventions
- DRUG Pioglitazone
- DRUG GW677954
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
What the finished NCT00196989 record still lists
NCT00196989 is an interventional study that assigns participants to a tested intervention. The registered 448 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher).
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00196989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00196989 about?
NCT00196989 is a clinical study titled "Study In People With Type 2 Diabetes". This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).
What is the current status of trial NCT00196989?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2005-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00196989?
The interventions under investigation include: Pioglitazone (DRUG), GW677954 (DRUG).
Who is sponsoring clinical trial NCT00196989?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00196989's enrollment target sits among peer trials
448 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia